Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 6, 2013, Pages 3625-3634

  Dedes, P G ^a   Kanakis, I ^a   Gialeli, Ch ^a,d   Theocharis, A D ^a   Tsegenidis, T ^a   Kletsas, D ^b   Tzanakakis, G N ^c   Karamanos, N K ^a,d  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

Bone metastasis; Breast cancer; Cellular model; Matrix macromolecule; Metalloproteinase

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BETA3 INTEGRIN; BIOLOGICAL MARKER; CATHEPSIN K; CELL SURFACE RECEPTOR; COLONY STIMULATING FACTOR 1; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN TRAP5B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVATION; CELL ADHESION; CELL MATURATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DECOMPOSITION; DRUG DETERMINATION; DRUG EFFECT; ENZYME MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MACROMOLECULE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PROPERTY; TUMOR MICROENVIRONMENT;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CATHEPSIN K; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMIDAZOLES; INTEGRIN BETA3; MACROPHAGE COLONY-STIMULATING FACTOR; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND;

EID: 84876004427     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.01.020     Document Type: Article

References (55)

1. H.K. Brown, and J.H. Healey Metastatic cancer to the bone V.T. De Vita, S. Hellman, S.A. Rosenberg, Principles and Practice of Oncology 2001 Lippincott Williams and Wilkins 2713 2729
2. R.V. Iozzo, and N.K. Karamanos Proteoglycans in health and disease: emerging concepts and future directions FEBS J. 277 19 2010 3863
3. R.E. Coleman, A. Lipton, G.D. Roodman, T.A. Guise, B.F. Boyce, A.M. Brufsky, P. Clézardin, P.I. Croucher, J.R. Gralow, P. Hadji, I. Holen, G.R. Mundy, M.R. Smith, and L.J. Suva Cancer Treat. Rev. 36 8 2010 615 620
4. L.A. Liotta, and E.C. Kohn The microenvironment of the tumour-host interface Nature 411 2001 375 379
5. I.J. Fidler Tumor heterogeneity and the biology of cancer invasion and metastasis Cancer Res. 38 1978 2651 2660
6. B.R. Zetter The cellular basis of site-specific tumor metastasis N. Engl. J. Med. 322 1990 605 612
7. Ch. Gialeli, A.D. Theocharis, and N.K. Karamanos Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting FEBS J. 278 1 2011 16 27
8. G.R. Mundy Bisphosphonates and tumor burden J. Clin. Oncol. 20 15 2002 3191 3192
9. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nature 2 2002 584 591
10. V.T. Labropoulou, A.D. Theocharis, A. Symeonidis, S.S. Skandalis, N.K. Karamanos, and H.P. Kalofonos Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions Curr. Med. Chem. 18 2011 1584 1598
11. J.J. Body, R. Bartl, P. Burckhardt, P.D. Delmas, I.J. Diel, H. Fleisch, J.A. Kanis, R.A. Kyle, G.R. Mundy, A.H. Paterson, and R.D. Rubens Current use of bisphosphonates in oncology J. Clin. Oncol. 16 1998 3890 3899
12. S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J. Bone Miner. Res. 13 1998 581 589
13. F.P. Coxon, and M.J. Rogers The role of prenylated small GTP-binding proteins in the regulation of osteoclast function Calcif. Tissue Int. 72 2003 80 84
14. G. Morgan, and A. Lipton Antitumor effects and anticancer applications of bisphosphonates Semin. Oncol. 37 2010 30 40
15. R.E. Coleman, M.C. Winter, D. Cameron, R. Bell, D. Dodwell, M.M. Keane, M. Gil, D. Ritchie, J.L. Passos-Coelho, D. Wheatley, R. Burkinshaw, S.J. Marshall, and H. Thorpe The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br. J. Cancer 102 2010 1099 1105
16. K. Zarogoulidis, E. Boutsikou, P. Zarogoulidis, E. Eleftheriadou, T. Kontakiotis, H. Lithoxopoulou, G. Tzanakakis, I. Kanakis, and N.K. Karamanos The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis Int. J. Cancer 125 2009 1705 1709
17. P.G. Dedes, Ch. Gialeli, A.I. Tsonis, I. Kanakis, A.D. Theocharis, D. Kletsas, G.N. Tzanakakis, and N.K. Karamanos Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid Biochim. Biophys. Acta 1820 2012 1926 1939
18. S. Boissier, S. Magnetto, L. Frappart, B. Cuzin, F.H. Ebetino, P.D. Delmas, and P. Clezardin Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices Cancer Res. 57 1997 3890 3894
19. V. Viereck, G. Emons, V. Lauck, K.H. Frosch, S. Blaschke, C. Grundker, and L.C. Hofbauer Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts Biochem. Biophys. Res. Commun. 291 2002 680 686
20. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, and T.J. Martin Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr. Rev. 20 3 1999 345 357
21. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, and T. Suda Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc. Natl. Acad. Sci. 95 1998 3597 3602
22. T. Onishi, N. Hayashi, R.L. Theriault, G.N. Hortobagyi, and N.T. Ueno Future directions of bone-targeted therapy for metastatic breast cancer Nat. Rev. Clin. Oncol. 7 11 2010 641 651
23. R. Hanada, T. Hanada, and J.M. Penninger Physiology and pathophysiology of the RANKL/RANK system Biol. Chem. 391 12 2010 1365 1370
24. C. Minkin Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function Calcif. Tissue Int. 34 1982 285 290
25. J.M. Halleen, H. Ylipahkala, S.L. Alatalo, A.J. Janckila, J.E. Heikkinen, H. Suominen, S. Cheng, and H.K. Väänänen Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density Calcif. Tissue Int. 71 1 2002 20 25
26. J.G. Schneider, S.R. Amend, and K.N. Weilbaecher Integrins and bone metastasis: integrating tumor cell and stromal cell interactions Bone 48 1 2011 9 (54-65)
27. R. Faccio, D.V. Novack, A. Zallone, F.P. Ross, and S.L. Teitelbaum Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin J. Cell Biol. 162 3 2003 499 509
28. P. Garnero, O. Borel, I. Byrjalsen, M. Ferreras, F.H. Drake, M.S. McQueney, N.T. Foged, P.D. Delmas, and J.M. Delaissé The collagenolytic activity of cathepsin K is unique among mammalian proteinases J. Biol. Chem. 273 48 1998 32347 32352
29. H. Sato, T. Takino, Y. Okada, J. Cao, A. Shinagawa, E. Yamamoto, and M. Seiki A matrix metalloproteinase expressed on the surface of invasive tumour cells Nature 370 6484 1994 61 65
30. M.T. Engsig, Q.J. Chen, T.H. Vu, A.C. Pedersen, B. Therkidsen, L.R. Lund, K. Henriksen, T. Lenhard, N.T. Foged, Z. Werb, and J.M. Delaissé Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones J. Cell Biol. 151 4 2000 879 889
31. P. Garnero, M. Ferreras, M.A. Karsdal, R. Nicamhlaoibh, J. Risteli, O. Borel, P. Qvist, P.D. Delmas, N.T. Foged, and J.M. Delaissé The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation J. Bone Miner. Res. 18 5 2003 859 867
32. S. Thiolloy, J. Halpern, G.E. Holt, H.S. Schwartz, G.R. Mundy, L.M. Matrisian, and C.C. Lynch Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis Cancer Res. 2 69 2009 6747 6755
33. R.J. Thomas, T.A. Guise, J.J. Yin, J. Elliott, N.J. Horwood, T.J. Martin, and M.T. Gillespie Breast cancer cells interact with osteoblasts to support osteoclast formation Endocrinology 140 1999 4451 4458
34. A.T. Mancino, V.S. Klimberg, M. Yamamoto, S.C. Manolagas, and E. Abe Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells J. Surg. Res. 100 1 2001 18 24
35. H. Morgan, A. Tumber, and P.A. Hill Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor Int. J. Cancer 109 2004 653 660
36. Y. Guo, K. Tiedemann, J.A. Khalil, C. Russo, P.M. Siegel, and S.V. Komarova Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation Bone 43 2 2008 386 393
37. Y.S. Lau, L. Danks, S.G. Sun, S. Fox, A. Sabokbar, A. Harris, and N.A. Athanasou RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer Breast Cancer Res. Treat. 105 1 2007 7 16
38. G.D. Roodman Cell biology of the osteoclast Exp. Hematol. 27 8 1999 1229 1241
39. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
40. K. Kusano, C. Miyaura, M. Inada, T. Tamura, A. Ito, H. Nagase, K. Kamoi, and T. Suda Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption Endocrinology 139 3 1998 1338 1345
41. K. Kimachi, H. Kajiya, S. Nakayama, T. Ikebe, and K. Okabe Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis Naunyn Schmiedebergs Arch. Pharmacol. 383 3 2011 297 308
42. M. Kellinsalmi, H. Mönkkönen, J. Mönkkönen, H.V. Leskelä, V. Parikka, M. Hämäläinen, and P. Lehenkari In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts Basic Clin. Pharmacol. Toxicol. 97 6 2005 382 391
43. R.H. Christenson Biochemical markers of bone metabolism: an overview Clin. Biochem. 30 8 1997 573 593
44. T.A. Guise, J.J. Yin, S.D. Taylor, Y. Kumagai, M. Dallas, B.F. Boyce, T. Yoneda, and G.R. Mundy Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis J. Clin. Invest. 98 1996 1544 1549
45. S.M. Käkönen, and G.R. Mundy Mechanisms of osteolytic bone metastases in breast carcinoma Cancer 97 Suppl. 3 2003 834 839
46. J.R. Green Antitumor effects of bisphosphonates Cancer 97 2003 840 847
47. C.L. Edward Zoledronic acid: a new parenteral bisphosphonate Clin. Ther. 25 2003 2669 2708
48. B. Pan, A.N. Farrugia, L.B. To, D.M. Findlay, J. Green, K. Lynch, and A.C. Zannettino The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE) J. Bone Miner. Res. 19 1 2004 147 154
49. P.S. Mackie, J.L. Fisher, H. Zhou, and P.F. Choong Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line Br. J. Cancer 84 7 2001 951 958
50. M. Nishikawa, T. Akatsu, Y. Katayama, Y. Yasutomo, S. Kado, N. Kugal, M. Yamamoto, and N. Nagata Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures Bone 18 1 1996 9 14
51. E.R. Van Beek, C.W. Löwik, and S.E. Papapoulos Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors Bone 30 1 2002 64 70
52. M.S. Bendre, A.G. Margulies, B. Walser, N.S. Akel, S. Bhattacharrya, R.A. Skinner, F. Swain, V. Ramani, K.S. Mohammad, L.L. Wessner, A. Martinez, T.A. Guise, J.M. Chirgwin, D. Gaddy, and L.J. Suva Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway Cancer Res. 65 23 2005 11001 11009
53. T. Yoneda, A. Sasaki, C. Dunstan, P.J. Williams, F. Bauss, Y.A. De Clerck, and G.R. Mundy Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2 J. Clin. Invest. 99 10 1997 2509 2517
54. P.A. Hill, J.J. Reynolds, and M.C. Meikle Inhibition of stimulated bone resorption in vitro by TIMP-1 and TIMP-2 Biochim. Biophys. Acta 1177 1 1993 71 74
55. T. Ohshiba, C. Miyaura, M. Inada, and A. Ito Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis Br. J. Cancer 88 8 2003 1318 1326